<DOC>
	<DOC>NCT02035644</DOC>
	<brief_summary>The aim of the present study is to evaluate the efficacy and safety of Jinlida granules in patients with inadequately controlled type-2 diabetes and dyslipidemia under life style intervention.</brief_summary>
	<brief_title>Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>1. age of 2070 years; 2. diagnosed with type 2 diabetes inadequately controlled under life style intervention with 3 months before screening; 3. HbA1c ≥6.5% and ≤10.0%, and fasting plasma glucose ≥7 and ≤13.3mmol/L at baseline; 4. diagnosed with dislipidemia with triglycerides&gt;150mg/dL (1.70mmol/L), and/or total cholesterol &gt;200mg/dL (5.16mmol/L), and/or LDLc&gt;100mg/dL (2.58mmol/L) 5. body mass index (BMI): 20&lt;BMI&lt;40 kg/m2; 1. moderate or severe liver dysfunction, abnormal renal function; 2. severe dysfunction of the heart; 3. histories of acute diabetic complications including diabetic ketoacidosis or hyperosmolar hyperglycemic nonketotic coma within 3 months; 4. psychiatric disease or severe infection; 5. pregnancy or planned pregnancy; 6. use of any drug (including insulin) for treatment of diabetes or dyslipidemia within 3 months; 7. use of chronic (&gt;7 days) systemic glucocorticoid therapy within 8 weeks or receive growth hormone therapy within 6 months; 8. diagnosed with type 1 diabetes, or gestational diabetes, or other specific types of diabetes; 9. history of malignant tumor within 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>